Alzheimer's disease, a progressive brain disorder caused by the degeneration of cells neurons, is currently ranked the seventh most common cause of death in the U.S., according to the National Institute of Aging. Agitation is one of the most disruptive and burdensome symptoms of dementia due to Alzheimer's disease, as it is associated with greater caregiver stress, increased morbidity and mortality. Otsuka Pharma/Lundbeck's Rexulti is the first and only FDA-approved drug to treat agitation symptoms associated with dementia due to Alzheimer's Disease. Unfortunately, this drug carries a black-box warning for mortality in elderly people.
The stock we are bringing to your attention today is that of a company aiming to capitalize on the substantial unmet medical need in the Alzheimer's disease agitation treatment landscape - Neumora Therapeutics Inc. (NMRA).
For comments and feedback: editorial@rttnews.com